ARNA: Summary for Arena Pharmaceuticals, Inc. - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 1:20am EST - Canadian Markets open in 8 hours and 10 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Arena Pharmaceuticals, Inc. (ARNA)

On Feb 9: 3.19 USD

0.10 (3.24%)

MORE ON ARNA

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Arena Pharmaceuticals, Inc. (NGM:ARNA) Delayed quote data

After Hours: 3.18

0.01 (0.31%) as of 6:57pm EST on 02/09/10

Last Trade:	3.19 USD
Trade Time:	Feb 9
Change:	0.10 (3.24%)
Prev Close:	3.09
Open:	3.15
Bid:	3.02 x 100
Ask:	3.45 x 100
1y Target Est:	6.32

Day's Range:	3.09 - 3.25
52wk Range:	2.26 - 7.42
Volume:	1,165,410
Avg Vol (3m):	1,674,990
Market Cap:	295.77M
P/E (ttm):	N/A
EPS (ttm):	-2.33
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Add ARNA to Portfolio

Download Data

HEADLINES

•	Premarket roundup: Visa, Cisco
	AP (Thu, Feb 4)

•	Ahead of the Bell: Arena Pharma upgraded
	AP (Thu, Feb 4)

•	Arena Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
	PRNewswire (Thu, Feb 4)

•	Arena Pharm upgraded by Rodman & Renshaw
	Briefing.com (Thu, Feb 4)

•	Orexigen shares rise on Jefferies analyst view
	AP (Tue, Feb 2)

•	ARENA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
	EDGAR Online (Wed, Jan 27)

•	Investors betting heavily on Vivus obesity drug
	at MarketWatch (Thu, Jan 21)

•	The Skinny On Vivus
	at CNBC (Wed, Jan 20)

•	Fat America
	at Forbes.com (Wed, Jan 13)

•	Vivus' Race Against The Clock
	at CNBC (Mon, Jan 11)

•	Peter Brimelow: 2009 top performer sees V-shaped recovery
	at MarketWatch (Fri, Jan 8)

More Headlines for ARNA...

ANALYST

EPS Est (next year) (Dec-09) :	-1.80
EPS Est (in 2 years) (Dec-10) :	-1.04
Avg Rec (current)*:	2.4
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing oral drugs in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•